Health Catalyst (NASDAQ:HCAT) Expected to Post Quarterly Sales of $37.74 Million

Equities analysts expect Health Catalyst (NASDAQ:HCAT) to announce sales of $37.74 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Health Catalyst’s earnings. The lowest sales estimate is $37.40 million and the highest is $38.08 million. The company is expected to issue its next quarterly earnings report on Thursday, November 28th.

On average, analysts expect that Health Catalyst will report full-year sales of $150.67 million for the current financial year, with estimates ranging from $150.20 million to $151.47 million. For the next year, analysts expect that the company will post sales of $183.26 million, with estimates ranging from $182.00 million to $184.79 million. Zacks’ sales averages are an average based on a survey of research firms that cover Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Thursday, August 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.13. The firm had revenue of $36.80 million during the quarter, compared to analysts’ expectations of $36.44 million. The company’s revenue for the quarter was up 60.1% compared to the same quarter last year.

HCAT has been the topic of a number of recent analyst reports. Svb Leerink assumed coverage on Health Catalyst in a research report on Monday, August 19th. They set an “outperform” rating and a $55.00 price target on the stock. Piper Jaffray Companies assumed coverage on shares of Health Catalyst in a report on Monday, August 19th. They issued an “overweight” rating and a $47.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Health Catalyst in a report on Monday, August 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Evercore ISI assumed coverage on shares of Health Catalyst in a research note on Monday, August 19th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, SunTrust Banks initiated coverage on shares of Health Catalyst in a research note on Monday, August 19th. They set a “buy” rating and a $53.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $51.29.

NASDAQ:HCAT traded up $1.29 during trading hours on Monday, reaching $35.33. The company’s stock had a trading volume of 162,733 shares, compared to its average volume of 342,309. Health Catalyst has a 12 month low of $32.15 and a 12 month high of $49.85.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

See Also: What is the price-sales ratio?

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.